Tuesday, November 03
Mutated & Non-Mutated Neoantigen Discovery by Proteogenomics
09:00 - 12:00
Times shown are in EST
Identification of the right candidate neoantigens to implement into next generation cancer vaccines and cell therapies is critical in determining the clinical success of these cancer immunotherapies. Whilst detection of mutated neoantigens by mass spectrometry and by prediction algorthims is feasible, it is essential to look towards other sources of neoantigens to accelerate development of neoantigen- based therapies further. There are a variety of different modalities used to identify the best neoantigen candidates as targets for anti-tumor treatments, however it is important to understand how to use these tools.
Group leader, Ludwig Institute for Cancer Research, Lausanne, Department of Oncology
University Hospital of Lausanne and the University of Lausanne
Attendees will learn and discuss:
• Mutated neoantigens that are rare and specific to a given patient
• How non-canonical (non-mutated) neoantigens, that are tumor specific and shared among patients, may be an additional source of immunogenic and clinically relevant target
• The need for implementation of proteogenomics computational pipelines, combining genomics, transcriptomics, immunopeptidomics and ribosome footprinting (Ribo-seq), to identify such non-canonical neoantigens
Michal Bassani-Sternberg is a group leader heading the Immunopeptidomics Unit. Her research group develops and implements advanced experimental and computational proteogenomics and mass-spectrometry based antigen discovery workflows to support development of personalized cancer immunotherapy and early phase experimental cancer vaccines.
Understanding the Relationship Between Genetics & Clinical Outcome: Personal Antigen Selection Calculator (PASCal) for the Design of Off-the-Shelf, Shared Neoantigen-Based Vaccines
13:00 - 16:00
Whilst one of the attractive features of neoantigen based therapies is its personalised nature, this does not come without practical and regulatory challenges. As the neoantigen space matures, and the clinical landscape continues to shift and evolve, it is important to look towards development of more cost effective and broadly applicable off-the-shelf neoantigen therapies.
Treos Bio LTD
In this workshop attendees will learn about:
• A vaccine design approach addressing both patient and tumor heterogeneity: leveraging cancer testis antigens as shared non-mutated neoantigens and an in silico human model demonstrated to predict clinical trial outcome
• A data reveal from phase I/II clinical trial with off-the-shelf vaccine against mCRC
• Improved selection of Personal Epitopes (PEPIs) that induce polyvalent cytotoxic T cell responses - exploring our personalised cancer vaccines proof of concept study
• How this technology leads to a shorter needle-to-needle time and more scalable products
Dr. Tőke has broad interdisciplinary experience of more than 15 years in translational research with special focus on preclinical/clinical development of therapeutic vaccines (on the field of HIV/AIDS, allergy and cancer). Previously, her research team developed Langerhans cell-targeting immunotherapies (DNA vaccine), nanomedicine delivery systems, pharmaceutically acceptable polymer syntheses (novel excipient) and medical device. Additionally, she has experience in regulatory affairs, GMP manufacturing and quality system establishment.